Novel immune checkpoint inhibitors hold promise for non-muscle-invasive bladder cancer. Cooperation between urologists and other multidisciplinary bladder cancer specialists can surmount the challenges involved in using these agents in bladder-sparing approaches.
This strategy could deliver a new era of comprehensive evaluation and multimodal treatment for this patient population.
European urology oncology. 2021 Jun 16 [Epub ahead of print]
Gianluca Giannarini, Neeraj Agarwal, Andrea B Apolo, Alberto Briganti, Petros Grivas, Shilpa Gupta, Ashish M Kamat, Francesco Montorsi, Morgan Rouprêt, Andrea Necchi
Urology Unit, Santa Maria della Misericordia University Hospital, Udine, Italy. Electronic address: ., Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Urology Unit, IRCCS San Raffaele Scientific Institute, Vita Salute University, Milan, Italy; Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy., Department of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA., Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., GRC 5 Predictive Onco-Uro, Sorbonne University, Urology, Pitié-Salpêtrière Hospital AP-HP, Paris, France., Urology Unit, IRCCS San Raffaele Scientific Institute, Vita Salute University, Milan, Italy; Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy; Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Vita Salute University, Milan, Italy.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/34147473